Notably, SGLT2 inhibitors promote glycosuria by lowering the renal glucose reabsorption threshold, whereas AVP promotes water reabsorption through stimulation of V2 receptors, and increased levels of AVP appear to limit glucose-induced water loss in patients with diabetes [43]. This evidence concerns the gene SLC5A2 and diabetes mellitus.